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Available online xxxxNanotechnology, although still in the early stages, has the potential to revolutionize the early diagnosis, treat-
ment, and monitoring of disease progression. Technological application of nanometer molecules in medicine
with the aim of ﬁghting and curing ailments is the globally deﬁnition of nanomedicine. The success of nanotech-
nology in the healthcare part is driven by the possibility to work at the same scale of several biological processes,
cellularmechanisms, and organicmolecules.With the growing understanding of methods to functionalize nano-
particles and the continued efforts of creative scientists to advance this technology, it is likely that functionalized
nanoparticles will become an important tool in the abovementioned areas. This paper describes the role of mul-
tifunctional nanoparticle in diagnosis and treatment of cancer. Therefore, the aimof this review is to provide basic
information on nanoparticles, describe previously developedmethods to functionalize nanoparticles and discuss
their potential applications in biomedical sciences and ﬁnally mention the therapeutic nanoparticle commercial-
ization challenges.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The number of new cases of cancer as one of the most deadly dis-
eases in the world increases each year [1]. With regards to positive out-
comes from early cancer diagnosis associated with a higher than 90% 5-
year survival rate [2,3] cancer therapy and detection technologies is an
emerging ﬁeld. This can provide rapid and sensitive detection of
cancer-related molecules, molecular changes detection even in a small
percentage of cells and also potential to generate novel and highly effec-
tive therapeutic agents [4–7]. Furthermore, there is a strong probability
that cancer nanotechnology could also open up opportunities for per-
sonalized cancer diagnosis and treatment approaches bymeans of mul-
tifunctional nanoparticles in four main area: detection of cancer
disease-speciﬁc biomarkers, imaging of tumors and their metastases,vanian).
. This is an open access article under
ultifunctional nanoparticle d
16/j.sbsr.2016.08.002the functional delivery of therapeutic agents to target cells, and real-
timemonitoring of treatment in progression. The purpose of this review
article is to summarize the results of use of multifunctional nanoparti-
cles in the cancer diagnosis, treatments and therapy and introduce the
different types of therapeutic nanoparticles. Thus, the ﬁrst part will em-
phasize the key properties of therapeutic multifunctional nanoparticles
and how these properties affect the efﬁciency and speciﬁcity of nano-
particles as a complicated and useful system. Next, we will summarize
current clinical uses of the therapeutic nanoparticles and new genera-
tion of therapeutic nanoparticles. Finally, we will discuss the challenges
for commercialization of therapeutic nanoparticles.1.1. Multifunctional nanoparticles
Multifunctional nanoparticle systems can integrate imaging,
targeting and treatment modalities both on the surface and in the corethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Nanoparticle application in cancer diagnosis and therapy [76].
Table 1
Different types of nanodevices are used in clinical application.
Modality Potential applications
Cantilevers • High-throughput screening
• Disease protein biomarker detection
• DNA mutation detection [SNPs]
• Gene expression detection
Carbon
nanotubes
• DNA mutation detection
• Disease protein biomarker detection
Dendrimers • Image contrast agents
Nanocrystals • Improved formulation for poorly soluble drugs
Nanoparticles • Targeted drug delivery, permeation enhancers
• MRI and ultrasound image contrast agents
• Reports of apoptosis, angiogenesis, etc.
Nanoshells • Tumor-speciﬁc imaging
Nanowires • High-throughput screening
• Disease protein biomarker detection
• DNA mutation Detection [SNPs]
• Gene expression detection
Quantum dots • Optical detection of genes and proteins in animals and cell
assays
• Tumor and lymph node visualization
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multaneous delivery of multiple treatment agents, to apply effective
combinatorial therapeutic regimens against cancer [9]. Different factors
contribute to multifunctional nanoparticle application resiliency, such
as tumor location in the body, the inability of the treatment to reach
the tumor cells, and the risk of damaging healthy cells (Fig. 1). Nanopar-
ticles provide an opportunity to change the pharmacokinetic outline of
drugs, reduce toxicity and enhance the therapeutic markers. This causes
the development of “multifunctional” nanoparticles. For this reason,
more capabilities like targeting and image contrast improvement are at-
tached to the nanoparticles. On the other hand, additional functionality
means additional synthetic steps and costs, more in vivo complex behav-
ior and effects, and also greater regulatory impediments [10]. Advances in
genomics and proteomics concepts have resulted in providing informa-
tion about the molecular proﬁles and biomarkers of different cancers, in
order to contribute in design of novel multifunctional NPs that can target
tumor cells with more accuracy and speciﬁcity. As a result, commerciali-
zation of nanoparticle-based therapeutics is increasing considerably,
with a rising in the number of available products on the market [4].
Nanomaterials that are used in medicine are including polymer carriers
[hydrogels, polymersomes, dendrimers, and nanoﬁbers] [11–23]; lipid-
based vehicles [liposomes, solid lipid nanoparticles, and micelles]
[24–26]; metallic nanoparticles [gold, silver, and titanium] [27–30];
carbon structures [nanotubes, nanohorns, nanodiamonds [NDs], and
graphene] [31–41]; and inorganic particles [silica] [42–45].
Highlighting attributes suchas adaptable surface chemistry, the ratio
of nanoparticles surface area-to-volume and the ability to
cofunctionalize nanoparticles, could competent nanomaterials for drug
binding and high drug-loading capacities. Considerably, these features
provide the possibilities for synthesis multimodal complexes for
destroying cancer tumor cells enhancement, detection and elimination
of cancer cells before they form tumors and highly sensitive imaging ca-
pabilities. One of the most important advantages of use of these nano-
particles is the possibility of reducing side effects as well as minimal
damage to healthy tissue and organs compared with conventional can-
cer therapeutic drugs [46–47]. Some physicochemical features of avail-
able potentially potent therapeutic agents [both biopharmaceutical and
small molecule drug related] such as large size, highly charged, too un-
stable metabolism and high insolubility, necessitate assistance of deliv-
ery vehicles to reach cancer target cells [48] [Table 1].
1.2. Cancer therapy and diagnosis
In spite of a huge number of researches about nanomedicine, unmet
medical demands in cancer diagnosis and therapy remain substantial.
Advanced multimodal imaging capabilities ensure diagnosis of diseasePlease cite this article as: S. Parvanian, et al., Multifunctional nanoparticle d
ing Research (2016), http://dx.doi.org/10.1016/j.sbsr.2016.08.002in early stages, real-time monitoring and discernment of its response
to the treatment regimen. David R J Snead and his colleagues provide
statistical evidence to demonstrate that digital pathology has advan-
tages over glass slid microscopy for the diagnosis of histopathology
[49]. Recent studies have also examined how the innate features of dif-
ferent types of nanomaterials in combination with induce biological re-
sponses and signals can be used to get tumors constricted [50–51].
Nanomedicine, however, will have the greatest impact when adminis-
tered in combination with traditional therapies, such as radiation and
cell therapy. Recent studies in animals suggest that timed combination
therapy in a researchwhere a siRNA and a drug are released sequential-
ly from liposomal nanoparticles could be the key to overcome
chemoresistance [52]. In order to reduce cancer drug resistance, combi-
nation chemotherapy has long been applied as a primary cancer treat-
ment regimen. Adapting multiple drugs with various molecular
targets increase the genetic obstacles to frustrate mutated cancer cells,
thereby delaying the cancer adaptation process. Furthermore, it has
also been illustrated that multiple drugs targeting in the same cellular
pathways could function synergistically in order to higher therapeutic
efﬁcacy and higher target selectivity [53].
The diagnosis and therapy approaches in some cancers, such as pan-
creatic and brain cancers, increase the use of nanoparticles potentially
for some reasons including the position of the tumor nearing theevelopments in cancer diagnosis and treatment, Sensing and Bio-Sens-
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of delivering treatment to the targeted organs, extensive adverse reac-
tions and negative response to conventional treatments techniques.
The infusion of nanomaterials into the bloodstream can accumulate in
tumors by the increased permeability and retention effect. When the
vasculature of immature tumor cells has pores smaller than 200 nm,
permitting extravasation of nanoparticles from blood into tumor tissue.
In addition to targeting cancer cells, targeting the tumor vasculature has
also illustrated to be a new method for targeted drug delivery [the best
instance is RGD-containing peptides for enhance integrins overexpressed
in tumor vasculature [73,74,75]].
As comparedwith conventional infusionmethod, the infusion of an-
tineoplastic drugs with nanomaterials as carriers led to an increased
payload of drugs to the tumor. In addition, by the Drug-loaded nanopar-
ticles, surfacemolecules can be overexpressed in tumor cells and there-
fore, by adding a targeting component, nanoparticles increased their
efﬁcacy of tumor-speciﬁc drug delivery beyond EPR-mediated tumor
homing, for example the polymeric particles such as BIND-014, with a
PSMA-targeting moiety on the surface and a docetaxel payload, has
been tested in humans clinical trials in early phase for metastatic can-
cers [77,78] [Table 2]. There are some new developments in the clinical
evaluation of transferrin receptor-targeted liposomal gene therapy that
can improve drug efﬁcacy by restoration of tumor suppressor genes
such as p53 and Rb94 [79–80].
Carbon nanomaterials, including nanotubes, nanohorns, fullerenols,
graphene, and NDs, have been used in delivering a wide spectrum of
therapeutic compounds with regards to their versatile surface proper-
ties [81–86].
RNAinterferences [RNAi] also can enhance drug delivery by silencing
cancer-causing genes, if can overcome enzymatic degradation in the
body [Table 3]. Cyclodextrin-based polymers [CDPs] is a good example
that are designed to protect and deliver siRNA tometastatic solidmalig-
nancies cancer cells [87–89].
Lipid based carriers with tumor-targeting and tumor-penetrating
moieties have been designed to improve delivery and enhance theTable 2
Liposomes, Polymeric nanoparticles and dendrimers for combination cancer therapy.
Formulation Drugs
CPX-351 5:1 cytarabine and daunoru
CPX-1 1:1 irinotecan and ﬂoxurid
CPX-571 7:1 irinotecan and cisplatin
Liposome co-encapsulating 6-mercaptopurine and
daunorubicin
6-Mercaptopurine and dau
Liposome co-encapsulating quercetin and vincristine 1:2 quercetin and vincristin
Cationic liposome co-encapsulating siRNA and doxorubicin Doxorubicin, MRP1-targete
BCL2-targeted siRNA
Transferrin-conjugated liposomes coencapsulating
doxorubicin and verapamil
Doxorubicin and verapami
HPMA–Gem–Dox Gemcitabine and doxorubi
Poly[ethylene glycol]–poly[aspartate hydrazide] block
copolymers–Dox–WOR
Doxorubicin and phosphat
kinase inhibitor [Wor]
Combretastatin–doxorubicin nanocell Combretastatin and doxoru
Core-shell nanoparticles Paclitaxel and Bcl-2-targete
PDMAEMA–PCL–PDMAEMA-based cationic micelles Paclitaxel and VEGF siRNA
Nanoparticle–aptamer bioconjugates Doxorubicin and docetaxel
Poly[lactic-co-glycolic acid] nanoparticle co-encapsulating
vincristine and verapamil
Vincristine and verapamil
Polyalkylcyanoacrylate nanoparticles co-encapsulating
doxorubicin and cyclosporin A
Doxorubicin and cyclospor
Generation-3 poly[L-lysine]
octa[3aminopropyl]silsesquioxane dendrimer
Doxorubicin and siRNA
Generation-5 poly[propyleneimine]dendrimer with
ethylenediamine core
Methotrexate and all-trans
Generation-4 polyamidoamine dendrimers Methotrexate and all-trans
Please cite this article as: S. Parvanian, et al., Multifunctional nanoparticle d
ing Research (2016), http://dx.doi.org/10.1016/j.sbsr.2016.08.002circulatory half-life of siRNA [90], for example siRNA nanocomplexes
that display a cyclic nanopeptide on its surface is able to penetrate
cells after being proteolytically processed by endogenous proteases.
These approaches ensured that the payload was only released once in-
side the cancer cell and ultimately cause that the particle was more
toxic to tumors than to healthy tissue.
One of the most important approaches to cancer diagnosis and ther-
apy is thermal therapy. Several classes of nanoparticles are used for
cancer thermal therapy such as magnetic, metallic and liposomes [91].
Photothermal therapy by using the heat to remove the cancer cells, has
gained interest for the inducible and noninvasive nature of this triggered
therapy and it can be applied to a huge number of solid tumors. Interest-
ing features of gold nanoshell encapsulating a silica core clinically include
biocompatibility of the particles as well as the tunability of the surface
plasmon resonance with regards to the ratio of the dielectric core radius
to shell thickness, make this class of nanoparticles to be effective in near-
infrared laser-induced cancer therapy in wide range of cancers such as
lung, prostate, and gliomas [92,93,94]. This especial nanoshell's design
provides highly efﬁcient and localized conversion of light to heat. During
the administration and photothermal ablation, the cancerous tissue vas-
culature was destroyed, whereas healthy tissue stays intact [95–96]. The
technology of nanoshells has been commercialized by Nanospectra
Biosciences as AuroLase, with clinical trials about the head and neck
cancer and primary and metastatic lung tumors.
In addition to photothermal therapy, magnetic and radio-based
strategies are being used for improving drug delivery and efﬁcacy
[97–98]. The basic concept of Radiotherapy is based on greater ab-
sorption of X-rays in cancerous tissue rather than the normal tissue.
One of the best example of Radio-induced nanomedicine is hafnium
oxide nanoparticles that enhanced energy deposit in nanoparticle-
containing subcellular cell structures and ﬁnally lead to enhanced
energy release and subsequent localized cellular destruction from
nanoparticle clusters. This method was tested clinically in patients
with soft tissue sarcoma of advanced squamous cell carcinoma of
the oral cavity [98].Indication Type Ref.
bicin Acute myeloid leukemia Liposome [54]
ine Colorectal cancer Liposome [55,56]
Small-cell lung cancer Liposome [57]
norubicin Acute lymphocytic leukemia Liposome [58]
e Breast cancers Liposome [59]
d siRNA and Lung cancer Liposome [60]
l Leukemia Liposome [61]
cin Prostate cancer and various cancer
types
Polymeric
nanoparticle
[62]
idylinositol-3 Breast cancer and various cancer
types
Polymeric
nanoparticle
[63]
bicin Lung carcinoma, melanoma and
various cancer types
Polymeric
nanoparticle
[64]
d siRNA Breast cancer Polymeric
nanoparticle
[65]
Prostate cancer and various cancer
types
Polymeric
nanoparticle
[66]
Prostate cancer and various cancer
types
Polymeric
nanoparticle
[67]
Breast cancer Polymeric
nanoparticle
[68]
in A Various cancer types Polymeric
nanoparticle
[69]
Glioblastoma Dendrimers [70]
retinoic acid Leukemia Dendrimers [71]
retinoic acid Leukemia Dendrimers [72]
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Table 3
Nanoparticle applications in drug delivery and cancer therapy.
Drug delivery
Agent delivered
key
Material[s] Translational
status
Details of study References
Doxorubicin Pluronic block
copolymers
Phase 2
clinical trials
P-glycoprotein-targeted chemotherapeutic delivery used against human gastroesophageal
adenocarcinoma
Acceptable safety proﬁle and enhanced efﬁcacy compared to free doxorubicin in phase 2
clinical trials [SP1049C-202-UK]
[106–107]
Docetaxel PEG-PLGA Phase 1
clinical trials
PSMA-targeted small-molecule-treated mouse xenografts of human prostate tumors
Ongoing clinical trials demonstrate favorable PK and initial efﬁcacy in human lung and
tonsillar cancers [NCT01300533, NCT01792479]
[108]
p53 or Rb94 plasmid Lipid Phase 1
clinical trials
Transferrin receptor-targeted liposomes enhanced delivery and transgene expression in
metastatic tumors in mouse metastatic pancreatic cancer
Ongoing clinical trials in patients with advanced solid tumors demonstrate favorable dose
response and successful overexpression of transgene in tumors compared to normal tissue
[NCT00470613, NCT01517464]
[109,110]
Paclitaxel Albumin Phase 1
clinical trials
Tumor vasculature-targeting and tumor-penetrating iRGD-coated Abraxane [nanoparticle
albumin-bound paclitaxel] exhibited enhanced tumor uptake and tumor growth inhibition of
mouse xenografts of human breast cancer compared to Abraxane treatment
Ongoing clinical trials are investigating the ability of iRGD to modify human metastatic breast
cancer permeability as measured by MRI [NCT01741597]
[111]
RRM2 siRNA Cyclodextrin-containing
polymers
Phase 1
clinical trial
Transferrin-mediated tumor targeting allowed knockdown of RRM2, which inhibited growth
of syngeneic graft murine neuroblastoma tumors
Phase 1 clinical trials in humans are ongoing as of 2008 and show evidence of RRM2
knockdown in metastatic human melanoma tumors [NCT00689065]
[112–113]
Cisplatin Carbon Preclinical Drug-loaded carbon nanohorns enhanced efﬁcacy in human lung cancer mouse xenograft
tumors in vivo compared to unmodiﬁed cisplatin
[114]
Paclitaxel Carbon Preclinical Drug-loaded single-walled carbon nanotubes enhanced circulation half-life, tumor killing, and
overall survival in 4T1 murine breast cancer model compared to unmodiﬁed paclitaxel
[115]
Doxorubicin Carbon Preclinical Drug-loaded NDs enhanced blood circulation, tumor killing, and animal survival in
chemoresistant mouse breast and liver tumors compared to unmodiﬁed doxorubicin
[116]
Epirubicin Carbon, lipid Preclinical EGFR-targeted, drug-loaded ND-lipid hybrid particle enhanced tumor homing and tumor
regression in a mouse model of human TNBC compared to free drug
[117]
ID4 siRNA Peptides Preclinical Tumor-penetrating peptide nanocomplexes loaded with siRNA-treated human ovarian
tumors in mice
[118]
Proprietary siRNA Carbon Preclinical Multiwalled carbon nanotubes loaded with siRNA inhibited tumor growth and prolonged
overall survival in human lung cancer xenografted mice compared to siRNA alone or liposomal
delivery of siRNA
[119]
Melittin peptide Carbon Preclinical Drug-loaded perﬂuorocarbon nanoparticles improved circulation and therapeutic efﬁcacy
against human breast cancer mouse xenograft tumors and syngeneic graft mouse melanoma
tumors compared to free drug
[120]
Bcl2L12 siRNA Gold Preclinical Gold-based spherical nucleic acid [SNA] delivery crossed BBB and accumulated in human
glioma tumors in mice to silence target gene and reduce tumor burden
[121]
Cancer therapy
Type of therapy Material[s] Translational
status
Key details of study References
Immunotherapy,
vaccine
Protein Phase 2
clinical trial
Viral-like protein shell delivery of CpG-rich oligodeoxynucleotide[CpG-ODN] and melanocyte
differentiation antigen resulted in enhanced CD8+ T cell response in melanoma patients
compared to antigen alone [NCT00651703]
[122]
Photothermal
vascular
Silica, gold Phase 1
clinical trials
endothelial growth factor [VEGF]-targeted nanoshellꞌs for thermal ablation and vessel
disruption in mouse glioma model Currently in clinical trials for head and neck
cancer[NCT00848042] and primary and/or metastatic lung tumors [NCT01679470]
[123]
Radiotherapy Hafnium oxide crystals Phase 1
clinical trials
Nanoparticles for radio-induced tumor cell killing in mesenchymal and epithelial tumor
xenograft mouse models
Phase 1 clinical trials are ongoing as of 2011
[NCT01946867, NCT01433068
[124]
Immunotherapy,
vaccine
Polysaccharide Phase 1
clinical trial
Her2 antigen cholesteryl mannan and cholesteryl pullulan nanoparticle vaccines previously
tested in Her2-expressing murine sarcomas Currently being evaluated in patients with
advanced cancer with Her2-expressing tumor
[125,126,127]
Immunotherapy,
vaccine
PLG Phase 1
clinical trial
PLG matrices that co-deliver granulocyte-macrophage colony-stimulating factor [GM-CSF],
CpG-ODN, and tumor lysate antigen for recruitment of DCs to PLG matrices, potent local and
systemic antitumor CD8+ T cell response in mouse melanoma model
Starting phase 1 study of implantable vaccine to treat melanoma [NCT01753089]
[128]
Magneto-responsive Iron/cobalt, PLGA Preclinical Magnetically guided polymer carriers loaded with Fe\\Co nanoparticle and doxorubicin for
drug-nanoparticle deposition in right or left liver lobe of rabbits
[129]
Immunotherapy,
vaccine
PEG-PLGA Preclinical Ovalbumin-loaded PEG-PLGA nanoparticles displaying RGD peptide for targeted M cell uptake
and vaccination in mice
[130]
Immunotherapy,
RNA adjuvant
Lipid Preclinical Lipidoid delivery of immunostimulatory RNA for antiviral and adjuvant activity in vivo in mice [131]
4 S. Parvanian et al. / Sensing and Bio-Sensing Research xxx (2016) xxx–xxxImmunotherapeutic approach based on enhancing the passive and
targeted delivery of antigens and adjuvants has the potential for remov-
ing the biological impediments in conventional methods such as oral
delivery [99,100,101]. One example is a delivery system contains aPlease cite this article as: S. Parvanian, et al., Multifunctional nanoparticle d
ing Research (2016), http://dx.doi.org/10.1016/j.sbsr.2016.08.002truncated Her2 protein complexed with hydrophobic polysaccharides
into nanoparticles in order to Her2 uptake high efﬁciency [102,103,
104]. Immune response was seen in 93% of patients that is satisfying
when compared to clinical trials with E75, an immunogenic peptideevelopments in cancer diagnosis and treatment, Sensing and Bio-Sens-
5S. Parvanian et al. / Sensing and Bio-Sensing Research xxx (2016) xxx–xxxfromHer2/neu protein,which sawpost vaccine delayed-type hypersen-
sitivity response in 74% of treated patients [105].
2. Commercialization challenges
Continuous advancements in nanomedicine have opened up oppor-
tunities for application of newgeneration ofmultifunctional therapeutic
nanoparticles in a variety of medical disciplines, but still we are facing
some basic challenges. There is a huge gap between nanobiotechnology
researches in labs and the production of commercialized therapeutic
nanoparticles. This gap contains a whole litany of challenges that must
be tackled. One of the most important challenges lies in scaling up pro-
cesses for production commercially. For a viable scale-up, laboratory
processes must be consistent with current manufacturing capabilities.
Another challenge is navigating an oftenmystifying regulatory perspec-
tive. Although nanoparticle based therapies refer to more complicated
requirements than conventional medical treatments [in that both re-
quire clinical trials that demonstrate safety and efﬁcacy, more compli-
cated technology needs more evidence of effectiveness. The human,
environment and animal safety that related to the life cycle issue also
are the main point for discuss. Detect and determine the toxicity of
engineered nanomaterials within next 5 to 15 years is an important
challenge for researchers, though, describemodels for predicting effects
of nanomaterials on human health and the environment would be an
inevitable issue. Finally, researchers should take a proactive role in
translating laboratory discoveries into feasible medical technology.
Such an important role requires researchers to consider future commer-
cialization early in their research and act accordingly.
3. The future of nanomedicine
In spite of a huge number of researches about nanomedicine, unmet
medical demands in cancer diagnosis and therapy remain substantial.
The potential for nanotechnology inmedicine, in the future of cancer di-
agnosis and therapy is unprecedented. Continuously drives advances in
diagnostic nanobiotechnological devices design, with diameters of hun-
dreds of atoms is a considerable progress that can revolutionized the
ability of cancer diagnosis especially about medical data collection, de-
tect chemical changes in the body, the ability of closer real-time tracking
of a patient's status and the build of nanoscale microscopic cameras. All
of these advancements can provide a completemap ofmost of the tissue
in the human body, in a level of detail that's impossible with X-ray or
MRI.With the application of quantumdots as anoptical barcodemay in-
deed gene sequencing and chemical analysis be speed up and ﬁnally it
provides the possibility of faster, cheaper and more reliable diagnostic
tests outside the body. The outcome of these progressions at cellular
and molecular levels will be result in the potential for diagnosing and
treating many conditions preemptively, before they have the opportu-
nity to proliferate.
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